破壞性行為障礙治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球破壞性行為障礙治療市場規模達 15 億美元，預計 2025 年至 2034 年期間的複合年成長率為 5.4%。該市場主要治療對立違抗性障礙 (ODD)、間歇性爆發性障礙 (IED) 和品行障礙 (CD) 等主要影響兒童和青少年的疾病。這些疾病的盛行率不斷上升，加上人們對心理健康意識的日益關注，推動了對有效治療方案的需求。隨著父母、教育工作者和醫療保健提供者認知到早期介入的重要性，對專門照護的需求日益成長。

此外，包括行為療法和藥物介入在內的治療方式的進步為治療這些疾病提供了更全面的解決方案。政府旨在改善心理健康服務和增加治療機會的措施進一步推動了市場成長。對實證治療的日益重視，加上評估新療法有效性的臨床研究數量的增加，預計將對市場擴張做出重大貢獻。此外，數位健康技術和遠距治療服務的整合使更廣泛的人群能夠接受治療，從而推動未來幾年的進一步成長。

市場主要分為三種障礙類型：品行障礙、間歇性爆發性障礙、對立性反抗障礙。品行障礙佔了最大的市場佔有率，2024 年的市場規模為 10 億美元。這種主導地位歸因於這種障礙在兒童和青少年中的高盛行率，其特徵是持續的攻擊性、破壞性和反社會行為模式。這些行為通常需要強化治療，包括藥物介入（例如抗精神病藥物）和行為療法。對個人化和多方面治療方案的需求不斷成長，推動了該領域的穩定成長。

破壞性行為障礙的治療方案包括藥物治療和心理治療，其中心理治療佔據市場主導地位。 2024 年，治療佔了 59.4% 的市場佔有率，預計到 2034 年將創造 15 億美元的市場價值。治療選項非常廣泛，包括家庭治療、認知行為療法 (CBT) 和社會情緒技能培訓，所有這些在解決情緒調節和改善家庭動態方面都發揮著至關重要的作用。治療仍然是最廣泛使用的治療方法，心理健康專家會制定干涉措施來滿足受影響個體的特定需求。藥物治療，包括抗精神病藥物和注意力不足過動症藥物，仍然是有效的輔助手段，特別是在單靠行為介入不夠的情況下。

2023 年，美國破壞性行為障礙治療市場產值達到 5.807 億美元，這得益於確診患者數量的不斷成長以及該國對醫療保健創新的持續投資。隨著對心理健康的關注度不斷提高，更有效的治療方法的發展正在促進市場持續成長。精神健康計畫資金的增加，加上研究計畫的增多，正在促進治療方案的進步，確保全國醫療服務的持續改善。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 行為障礙盛行率上升
    • 數位療法的整合
    • 提高認知和早期診斷
    • 不斷發展的政府政策和支持
  • 產業陷阱與挑戰
    • 與精神健康障礙相關的社會恥辱
• 成長潛力分析
• 監管格局
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：依疾病類型，2021 年至 2034 年

• 主要趨勢
• 對立違抗性障礙
• 品行障礙
• 間歇性暴發性障礙

第6章：市場估計與預測：依治療類型，2021 年至 2034 年

• 主要趨勢
• 藥物
  • 抗精神病藥物
  • 興奮劑
  • 非興奮劑型ADHD藥物
  • 其他藥物
• 治療
  • 綜合評價
  • 家庭治療
  • 父母教養修改
  • 團體治療
  • 個別治療
  • 社交和情緒技能培訓

第7章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 精神病診所
• 復健中心
• 其他最終用途

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國

第9章：公司簡介

• Drugs:
• Therapy:

The Global Disruptive Behavior Disorder Treatment Market generated USD 1.5 billion in 2024 and is projected to grow at a CAGR of 5.4% between 2025 and 2034. This market addresses conditions such as oppositional defiant disorder (ODD), intermittent explosive disorder (IED), and conduct disorder (CD), which primarily affect children and adolescents. The rising prevalence of these disorders, coupled with an increasing focus on mental health awareness, is driving the demand for effective treatment options. As parents, educators, and healthcare providers recognize the importance of early intervention, the need for specialized care is growing.

Moreover, advancements in treatment modalities, including behavioral therapies and pharmacological interventions, are offering more comprehensive solutions for managing these disorders. Government initiatives aimed at improving mental health services and increasing access to treatment are further boosting market growth. The growing emphasis on evidence-based therapies, coupled with an increasing number of clinical studies to evaluate the effectiveness of new treatments, is expected to contribute significantly to the market's expansion. Additionally, the integration of digital health technologies and teletherapy services is making treatment more accessible to a wider demographic, driving further growth in the coming years.

The market is segmented into three primary disorder types: conduct disorder, intermittent explosive disorder, and oppositional defiant disorder. Conduct disorder accounted for the largest share of the market, generating USD 1 billion in 2024. This dominance is attributed to the high prevalence of the disorder among children and adolescents, characterized by persistent patterns of aggressive, disruptive, and antisocial behaviors. These behaviors often necessitate intensive treatment involving both pharmacological interventions, such as antipsychotic medications, and behavioral therapies. The increasing need for personalized and multi-faceted treatment options has fueled the steady growth of this segment.

Treatment options for disruptive behavior disorders include both medications and therapy, with the therapy segment dominating the market. Therapy accounted for 59.4% of the market share in 2024 and is expected to generate USD 1.5 billion by 2034. Therapy options are extensive and include family therapy, cognitive-behavioral therapy (CBT), and social-emotional skills training, all of which play a crucial role in addressing emotional regulation and improving family dynamics. Therapy remains the most widely utilized treatment approach, with mental health professionals tailoring interventions to meet the specific needs of affected individuals. Pharmacological treatments, including antipsychotics and ADHD medications, continue to serve as valuable adjuncts, particularly in cases where behavioral interventions alone are insufficient.

The U.S. disruptive behavior disorder treatment market generated USD 580.7 million in 2023, driven by a growing number of diagnosed individuals and the country's ongoing investment in healthcare innovations. As the focus on mental health intensifies, the development of more effective therapies is contributing to sustained market growth. Increased funding for mental health programs, coupled with a rise in research initiatives, is fostering the advancement of treatment options, ensuring continuous improvements in care delivery across the country.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of behavioral disorders
    • 3.2.1.2 Integration of digital therapeutics
    • 3.2.1.3 Increasing awareness and early diagnosis
    • 3.2.1.4 Evolving government policies and support
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Social stigma associated with mental health disorders
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Gap analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disorder Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Oppositional defiant disorder
• 5.3 Conduct disorder
• 5.4 Intermittent explosive disorder

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drugs
  • 6.2.1 Antipsychotics
  • 6.2.2 Stimulants
  • 6.2.3 Non-stimulant ADHD medications
  • 6.2.4 Other drugs
• 6.3 Therapy
  • 6.3.1 Comprehensive evaluation
  • 6.3.2 Family therapy
  • 6.3.3 Parenting modification
  • 6.3.4 Group therapy
  • 6.3.5 Individual therapy
  • 6.3.6 Social and emotional skills training

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Psychiatric clinics
• 7.4 Rehabilitation centers
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Drugs:
  • 9.1.1 Bionomics
  • 9.1.2 Eli Lilly and Company
  • 9.1.3 Johnson & Johnson
  • 9.1.4 Mylan
  • 9.1.5 Novartis
  • 9.1.6 Pfizer
  • 9.1.7 Takeda Pharmaceuticals
• 9.2 Therapy:
  • 9.2.1 Boston Children's Hospital
  • 9.2.2 Highland Ridge Hospital
  • 9.2.3 INTEGRIS Health
  • 9.2.4 Lakeview Health
  • 9.2.5 Springwoods Behavioral Health